<DOC>
	<DOCNO>NCT00004300</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine difference person repetitive behavior disorder match control measure motor control relevant basal ganglia pathophysiology . II . Determine efficacy bromocriptine , dopamine agonist , treatment stereotype behavior relate behavior disorder . III . Determine efficacy sertraline hydrochloride , selective serotonin uptake inhibitor , treatment repetitive behavior disorder . IV . Identify behavioral , environmental , biological variable differential drug treatment response .</brief_summary>
	<brief_title>Phase II Study Stereotypes Mental Retardation : Neurobiological Basis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Motor slowness ( bradykinesia ) motor control test repetitive behavior disorder patient match control . Group differences reflect alteration basal ganglia dopamine function compare . Behavioral assessment conduct patient trained observer . Assessments take baseline maintenance phase drug treatment describe . The efficacy bromocriptine treatment stereotypy self-injury determine randomize , double blind , placebo control , crossover study extend 20 week . Cohorts 6 8 patient first enter single blind placebo phase , follow double blind treatment placebo bromocriptine . The crossover manipulation entail titration phase , maintenance phase , final single blind placebo condition . The experimental design use determine efficacy sertraline placebo treatment stereotypy concomitant self injury compulsion . Duration study 26 week .</detailed_description>
	<mesh_term>Intellectual Disability</mesh_term>
	<mesh_term>Stereotypic Movement Disorder</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis mental retardation High rate stereotype behavior , concomitant selfinjurious compulsive behavior No diagnosis tardive dyskinesia akathisia Prior/Concurrent Therapy No exposure neuroleptic within 6 month prior study Patient Characteristics Age : 18 55 Hematopoietic : ( bromocriptine sertraline treatment ) No history anemia No clinically significant hematologic disease Hepatic : ( bromocriptine sertraline treatment ) No history hepatic abnormalities No clinically significant liver disease Renal : ( bromocriptine sertraline treatment ) No history renal abnormalities No clinically significant renal disease Cardiovascular : ( bromocriptine sertraline treatment ) No history hypertension No clinically significant cardiac disease Other : No history seizure within 4 month prior study ( bromocriptine sertraline treatment ) No history sensitivity ergot alkaloid ( bromocriptine treatment ) No sensitivity serotonin uptake inhibitor ( sertraline treatment ) No patient sensory deficit ( motor function assessment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>mental retardation</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>stereotype behavior</keyword>
</DOC>